ClinicalTrials.gg
RecruitingNCT07873541Updated Oct 14, 2026

Comparison of Different Exercise Protocols for Diagnosed With Lipedema

An interventional study of High-Intensity Interval Aerobic Exercise Group and Moderate Intensity Continuous Group in Aerobic Exercise and Lipedema, sponsored by Hitit University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Hitit University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Oct 14, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study was designed to compare the effects of high-intensity interval training and moderate-intensity continuous training on functional capacity, muscle strength, and quality of life in patients with lipedema, and to determine the most effective exercise training protocol for this population.

02

Conditions studied

  • Aerobic Exercise
  • Lipedema

Browse trials for

Keywords

  • lipedema
  • aerobic exercise training
  • functional capacity
  • muscle strength
  • quality of life
03

In context

Lipedema

83 studies on the registry are indexed under Lipedema; 31 are open to participants now.

This study's planned enrollment of 66 is above the median of 35 across 40 interventional studies indexed under Lipedema.

Browse Lipedema studies →

Lead sponsor

Hitit University is the lead sponsor of 84 studies on the registry; 30 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18-65 years and diagnosed with lipedema.
  • Have not participated in a structured exercise training program within the previous 3 months.
  • Voluntarily agree to participate in the study and provide informed consent.

Exclusion criteria

Exclusion Criteria:

  • Presence of cardiopulmonary, rheumatologic, or neurological conditions causing symptoms of sufficient severity to prevent participation in the exercise program.
  • History of cancer or presence of thyroid disorders.
  • Presence of edema primarily attributable to conditions other than lipedema, including lymphedema, venous edema, or edema secondary to heart or renal failure.
  • Body mass index (BMI) > 50.0 kg/m².
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
66 participants (estimated)

Study arms

  • Experimental
    High-Intensity Interval Aerobic Exercise Group

    High-intensity interval lower-extremity aerobic exercise training will be performed on a cycle ergometer for a total duration of 35 minutes. The exercise protocol will consist of a 5-minute warm-up period at 50% of maximum heart rate, a 4 × 4-minute high-intensity training period at 80-95% of maximum heart rate, a 3 × 3-minute active recovery period at 70% of maximum heart rate, and a 5-minute cool-down period at 50% of maximum heart rate.

    Other: High-Intensity Interval Aerobic Exercise Group

  • Experimental
    Moderate-Intensity Continuous Aerobic Exercise Group

    Moderate-intensity continuous lower-extremity aerobic exercise training will be performed on a cycle ergometer for a total duration of 35 minutes. The exercise protocol will consist of a 5-minute warm-up period at 50% of maximum heart rate, a 25-minute moderate-intensity training period at 65-70% of maximum heart rate, and a 5-minute cool-down period at 50% of maximum heart rate.

    Other: Moderate Intensity Continuous Group

  • No intervention
    Control Group

    No intervention will be performed; exercise recommendations will be provided only during routine control.

Interventions

  • OtherHigh-Intensity Interval Aerobic Exercise Group

    High-intensity interval lower-extremity aerobic exercise training will be performed on a cycle ergometer for a total duration of 35 minutes. The exercise protocol will consist of a 5-minute warm-up period at 50% of maximum heart rate, a 4 × 4-minute high-intensity training period at 80-95% of maximum heart rate, a 3 × 3-minute active recovery period at 70% of maximum heart rate, and a 5-minute cool-down period at 50% of maximum heart rate.

  • OtherModerate Intensity Continuous Group

    Moderate-intensity continuous lower-extremity aerobic exercise training will be performed on a cycle ergometer for a total duration of 35 minutes. The exercise protocol will consist of a 5-minute warm-up period at 50% of maximum heart rate, a 25-minute moderate-intensity training period at 65-70% of maximum heart rate, and a 5-minute cool-down period at 50% of maximum heart rate.

06

What researchers measure

Primary outcomes

  1. Functional capacity

    Functional capacity will be assessed using symptom-limited maximal cardiopulmonary exercise testing (CPET), which is considered the gold-standard method for evaluating exercise capacity. CPET will be performed on a cycle ergometer (Corival CPET, Lode, Groningen, the Netherlands).

    Time frame: Baseline and after treatment (6 weeks)

  2. Handgrip strength

    Hand grip strength will be assessed using a hydraulic hand dynamometer (Baseline Hydraulic Hand Dynamometer, Model 12-0240, Fabrication Enterprises Inc., White Plains, NY, USA). Measurements will be performed in a seated position with the shoulder adducted, the elbow flexed at 90°, and the forearm in a neutral position. Three measurements will be performed for each hand (right and left), and the highest value obtained from each side will be recorded for statistical analysis.

    Time frame: Baseline and after treatment (6 weeks)

  3. Health-related quality of life

    Quality of life will be assessed using the 36-Item Short Form Health Survey (SF-36). The SF-36 is a patient-centered, general health assessment instrument designed to evaluate an individual's overall perception of health and quality of life. It consists of 36 items covering eight domains: physical functioning, role limitations due to physical health problems, role limitations due to emotional problems, vitality, social functioning, bodily pain, general health perceptions, and mental health. The questionnaire includes 11 questions, and each domain is scored on a scale ranging from 0 to 100. Higher scores indicate better perceived health and quality of life.

    Time frame: Baseline and after treatment (6 weeks)

Secondary outcomes

  1. Fatigue

    Fatigue will be assessed using the Fatigue Severity Scale (FSS). The FSS is a 9-item scale designed to assess the severity of fatigue and its impact on daily activities and lifestyle in individuals with various health conditions. Each item is rated on a 7-point scale ranging from 1 (strongly disagree) to 7 (strongly agree). The total score ranges from 9 to 63, with higher scores indicating greater fatigue severity.

    Time frame: Baseline and after treatment (6 weeks)

  2. Anxiety and Depression

    Anxiety and depression will be assessed using the Hospital Anxiety and Depression Scale (HADS). The HADS is a self-administered instrument developed to identify the risk and severity of anxiety and depression and to assess changes in symptom severity among patients with physical illnesses and individuals attending primary healthcare services. The scale consists of 14 items divided into two subscales: anxiety (HADS-A) and depression (HADS-D), with 7 items in each subscale. Each subscale is scored from 0 to 21, with higher scores indicating greater severity of anxiety or depression. Cut-off scores of ≥10 for the anxiety subscale and ≥7 for the depression subscale have been established to indicate clinically relevant symptoms.

    Time frame: Baseline and after treatment (6 weeks)

07

Study locations

1 of 1 sites recruiting
  • Hitit University
    Çorum, 19000, Turkey (Türkiye)
    Recruiting
08

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07873541
Lead sponsor
Hitit University
Responsible party
Ayla Cagliyan Turk (Prof. Dr., Hitit University) — Principal investigator
First posted
Oct 14, 2026
Start date
Sep 11, 2026
Primary completion
Sep 11, 2027 (estimated)
Completion
Sep 11, 2027 (estimated)
Last update
Oct 14, 2026

Study contacts

Ayla Cağlıyan Turk
Contact
drayla1976@hotmail.com
+095334314171

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion